Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LGALS9/Galectin-9 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LGALS9 Recombinant Protein (N- & C-CRD domains) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View LGALS9 Products |
| Gene Delivery | LGALS9 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View LGALS9 Products |
| Benchmark Ab | Anti-LGALS9 Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View LGALS9 Products |
| Validator | LGALS9 siRNA Set For target knockdown validation and specificity verification. |
View LGALS9 Products |
| Related Target A | HAVCR2 (TIM-3) Primary receptor for Galectin-9; key immune checkpoint pathway in T-cell exhaustion. |
View HAVCR2 Products |
| Related Target B | PDCD1 (PD-1) Synergistic checkpoint target; co-blockade of PD-1 and Gal-9/TIM-3 restores immune response. |
View PDCD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Non-specific glycan binding interference | HEK293 Expressed (Native Glycosylation) ensuring correct folding and natural post-translational modifications. |
| Protein aggregation and instability | High Purity (>95% by SDS-PAGE) and optimized formulation buffer to maintain monomeric state. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included as assay positive controls. |
| False Positives | Validated siRNA included for target-specific knockdown verification. |
Live LGALS9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LGALS9 therapeutics is intensifying, with major players shifting focus from traditional mAbs to combination therapies and multispecific modalities. As first-generation therapies reach the clinic, the next wave of R&D is targeting the suppression of the TIM-3/Galectin-9 axis to overcome resistance to PD-1/PD-L1 inhibitors in solid tumors and AML.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | BMS, Lycera | Solid Tumors, AML | Blocking Assay (Need high-purity LGALS9 and HAVCR2/TIM-3 proteins) |
| Bispecific Antibody | Invenra, Roche | Immuno-oncology | Dual-targeting validation (Need highly stable recombinant proteins) |
| Small Molecule Inhibitors | Academic Consortia | Autoimmune, Inflammation | High-throughput screening (Need sequence-verified monomeric proteins) |